In 2007, the European Union adopted a lex specialis, Regulation (EC) No. 1394/2007 on advanced therapy medicinal products (ATMPs), a new legal category of medical product in regenerative medicine. The regulation applies to ATMPs prepared industrially or manufactured by a method involving an industrial process. It also provides a hospital exemption, which means that medicinal products not regulated by EU law do not benefit from a harmonized regime across the European Union but have to respect national laws. This article describes the recent EU laws, and contrasts two national regimes, asking how France and the United Kingdom regulate ATMPs which do and do not fall under the scope of Regulation (EC) No. 1394/2007. What are the different legal...
The regulatory evolution of medical technologies in the European Union offers a unique perspective w...
International audienceIn relation to the “hot” topic of regenerative medicine, European Union law es...
Aim: To study regulatory approaches for the implementation and utilization of the Hospital Exemption...
In 2007, the European Union adopted a lex specialis, Regulation (EC) No. 1394/2007 on advanced thera...
Les produits de santé fabriqués à base de gènes, cellules et tissus, interrogent les cadres juridiqu...
Advanced therapy medicinal products (ATMPs) are a fast-growing field of innovative therapies. The Eu...
BACKGROUND AIMS: As part of the advanced therapy medicinal product (ATMP) regulation, the hospital e...
Advanced Therapy Medicinal Products (ATMPs) is a European classification of medicinal products based...
Genes, cells, and tissues based medicinal products are specifically regulated as Advanced Therapy Me...
N/AIn Europe, advanced therapy medicinal products (ATMPs), including cell and gene medicinal produc...
The market authorisation procedure for medicinal products for human use is relying on their demonstr...
International audienceAdvanced Therapy Medicinal Products (ATMPs), a European legal classification o...
The transplantation of conventional human cell and tissue grafts, such as heart valve replacements a...
Even for centrally approved products, each European country is responsible for the effective nationa...
Advanced Therapy Medicinal Products (ATMPs) is a European classification of medicinal products based...
The regulatory evolution of medical technologies in the European Union offers a unique perspective w...
International audienceIn relation to the “hot” topic of regenerative medicine, European Union law es...
Aim: To study regulatory approaches for the implementation and utilization of the Hospital Exemption...
In 2007, the European Union adopted a lex specialis, Regulation (EC) No. 1394/2007 on advanced thera...
Les produits de santé fabriqués à base de gènes, cellules et tissus, interrogent les cadres juridiqu...
Advanced therapy medicinal products (ATMPs) are a fast-growing field of innovative therapies. The Eu...
BACKGROUND AIMS: As part of the advanced therapy medicinal product (ATMP) regulation, the hospital e...
Advanced Therapy Medicinal Products (ATMPs) is a European classification of medicinal products based...
Genes, cells, and tissues based medicinal products are specifically regulated as Advanced Therapy Me...
N/AIn Europe, advanced therapy medicinal products (ATMPs), including cell and gene medicinal produc...
The market authorisation procedure for medicinal products for human use is relying on their demonstr...
International audienceAdvanced Therapy Medicinal Products (ATMPs), a European legal classification o...
The transplantation of conventional human cell and tissue grafts, such as heart valve replacements a...
Even for centrally approved products, each European country is responsible for the effective nationa...
Advanced Therapy Medicinal Products (ATMPs) is a European classification of medicinal products based...
The regulatory evolution of medical technologies in the European Union offers a unique perspective w...
International audienceIn relation to the “hot” topic of regenerative medicine, European Union law es...
Aim: To study regulatory approaches for the implementation and utilization of the Hospital Exemption...